Invivyd, Inc.

Biotechnology • Healthcare • Waltham, MA, United States • IVVD (NGM)

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

781 819 0080 1601 Trapelo Road, Waltham, MA 02451, United States

Stock Performance (90 Days)

Data through Dec 30, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

$IVVD stock is down 13% today. Here's what we see in our data. - Quiver Quantitative

Quiver Quantitative • Dec 2

Invivyd stock initiated with Buy rating at BTIG on COVID antibody potential By Investing.com - Investing.com South Africa

Investing.com South Africa • Dec 22

BTIG Research Upgrades Invivyd (NASDAQ:IVVD) to Strong-Buy - MarketBeat

MarketBeat • Dec 24

Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Yahoo Finance • Nov 6

Invivyd: Why I’m Selling The CDTX Read-Through Rally (NASDAQ:IVVD) - Seeking Alpha

Seeking Alpha • Nov 19

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Invivyd, Inc. had layoffs?

No layoff events have been recorded for Invivyd, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Invivyd, Inc. have?

Invivyd, Inc. has approximately 99 employees.

What industry is Invivyd, Inc. in?

Invivyd, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Invivyd, Inc. a publicly traded company?

Yes, Invivyd, Inc. is publicly traded under the ticker symbol IVVD on the NGM. The company has a market capitalization of approximately $0.60 billion.

Where is Invivyd, Inc. headquartered?

Invivyd, Inc. is headquartered in Waltham, MA, United States at 1601 Trapelo Road, Waltham, MA 02451, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.